{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:38:31Z","timestamp":1773772711879,"version":"3.50.1"},"reference-count":16,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1134\/s1607672924701084","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T10:03:22Z","timestamp":1724839402000},"page":"382-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study"],"prefix":"10.1134","volume":"518","author":[{"given":"Sh.","family":"Erdes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. I.","family":"Mazurov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Z.","family":"Gaydukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Anoshenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. B.","family":"Vinogradova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu. Yu.","family":"Grabovetskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Y.","family":"Davidian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. A.","family":"Kiryukhina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. E.","family":"Epifanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. V.","family":"Masneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. V.","family":"Menshikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Mironenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. E.","family":"Nikulenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. V.","family":"Povarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. N.","family":"Poliatika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Samigullina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Sizikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. N.","family":"Totrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. F.","family":"Umnova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. V.","family":"Usacheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Chudinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"7574_CR1","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","volume":"1","author":"J. Sieper","year":"2015","unstructured":"Sieper, J., Braun, J., Dougados, M., and Baeten, D., Axial spondyloarthritis, Nat. Rev. Dis. Prim., 2015, vol.\u00a01, p. 15013.","journal-title":"Nat. Rev. Dis. Prim."},{"key":"7574_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.55563\/clinexprheumatol\/lycdc8","volume":"39","author":"M. Merino","year":"2021","unstructured":"Merino, M., Bra\u00e7e, O., Gonz\u00e1lez-Dom\u00ednguez, A., et\u00a0al., Social economic costs of ankylosing spondylitis in Spain, Clin. Exp. Rheumatol., 2021, vol. 39, no. 2, pp.\u00a0357\u2013364.","journal-title":"Clin. Exp. Rheumatol."},{"key":"7574_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.berh.2015.04.002","volume":"29","author":"R. Shukla","year":"2015","unstructured":"Shukla, R. and Goodacre, J., The impact of ankylosing spondylitis\/axial spondyloarthritis on work productivity, Best Pract. Res. Clin. Rheumatol., 2015, vol. 29, no.\u00a03, pp. 512\u2013523.","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"7574_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S. Ramiro","year":"2023","unstructured":"Ramiro, S., Nikiphorou, E., Sepriano, A., et al., ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update, Ann. Rheum. Dis., 2023, vol. 82, pp. 19\u201334.","journal-title":"Ann. Rheum. Dis."},{"key":"7574_CR5","first-page":"474","volume":"55","author":"I.Z. Gaidukova","year":"2017","unstructured":"Gaidukova, I.Z., Rebrov, A.P., and Lapshina, S.A., Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization \u201cThe Association of Rheumatology of Russia\u201d, Nauchno-Prakt. \n               Revmatol., 2017, vol. 55, no. 5, pp.\u00a0474\u2013484.","journal-title":"Revmatol."},{"key":"7574_CR6","first-page":"376","volume":"58","author":"V.I. Mazurov","year":"2020","unstructured":"Mazurov, V.I., Gaydukova, I.Z., Erdes, Sh., Dubinina, T.V., Pristrom, A.M., et al., Efficacy and safety of Netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5\/ASTERA, Nauchno-Pract. \n               Revmatol., 2020, vol. 58, no. 4, pp. 376\u2013386.","journal-title":"Revmatol."},{"key":"7574_CR7","first-page":"39","volume":"14","author":"V.I. Mazurov","year":"2020","unstructured":"Mazurov, V.I., Erdes, Sh., Gaydukova, I.Z., et al., Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5\/ASTERA, Sovr. \n               Revmatol., 2020, vol. 14, no. 4, pp. 39\u201349.","journal-title":"Revmatol."},{"key":"7574_CR8","first-page":"718","volume":"41","author":"V.I. Mazurov","year":"2022","unstructured":"Mazurov, V.I., Dubinina, T.V., Erdes, S., Lapshina, S.A., Soroka, N.F., Kunder, E.V., Smirnov, A.V., Eremeeva, A.V., Zinkina-Orikhan, A.V., Morozova, M.A., and Gaydukova, I.Z., Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study, Clin. Exp. Rheumatol., 2022, vol. 41, no. 3, pp. 718\u2013726.","journal-title":"Clin. Exp. Rheumatol."},{"key":"7574_CR9","first-page":"351","volume":"56","author":"A.I. Akulova","year":"2018","unstructured":"Akulova, A.I., Gaydukova, I.Z., and Rebrov, A.P., Validation of the EQ-5D-5L version in Russia, Nauchno-Prakt. \n               Revmatol., 2018, vol. 56, no. 3, pp. 351\u2013355.","journal-title":"Revmatol."},{"key":"7574_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(05)66516-6","volume":"365","author":"K.F. Schulz","year":"2005","unstructured":"Schulz, K.F. and Grimes, D.A., Multiplicity in randomised trials II: subgroup and interim analyses, Lancet, 2005, vol. 365, no. 9471, pp. 1657\u20131661.","journal-title":"Lancet"},{"key":"7574_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.21037\/atm-23-195","volume":"11","author":"C. Tian","year":"2023","unstructured":"Tian, C., Shu, J., Shao, W., Zhou, Z., Guo, H., and Wang, J., Efficacy and safety of IL inhibitors, TNF-\u03b1 inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis, Ann. Transl. Med., 2023, vol. 11, no. 4, p. 178.","journal-title":"Ann. Transl. Med."},{"key":"7574_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","volume":"21","author":"U. Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m, U., Olofsson, T., Wedr\u00e9n, S., et al., Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice, Arthritis Res. Ther., 2019, vol. 21, p. 128.","journal-title":"Arthritis Res. Ther."},{"key":"7574_CR13","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1136\/annrheumdis-2022-eular.4138","volume":"81","author":"M. Gomez Vargas","year":"2022","unstructured":"Gomez Vargas, M. and Mu\u00f1oz, L., MAB0772 Safety and survival analysis of secukinumab treatment in a cohort of rheumatic patients na\u00efve to biological therapy, Ann. Rheum. Dis., 2022, vol. 81, p. 1512.","journal-title":"Ann. Rheum. Dis."},{"key":"7574_CR14","doi-asserted-by":"publisher","first-page":"e001280","DOI":"10.1136\/rmdopen-2020-001280","volume":"6","author":"B. Michelsen","year":"2020","unstructured":"Michelsen, B., Lindstr\u00f6m, U., Codreanu, C., et al., Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration, RMD Open, 2020, vol. 6, no. 3, p. e001280.","journal-title":"RMD Open"},{"key":"7574_CR15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3389\/fimmu.2017.01589","volume":"8","author":"M. Arbabi-Ghahroudi","year":"2017","unstructured":"Arbabi-Ghahroudi, M., Camelid single-domain antibodies: Historical perspective and future outlook, Front. Immunol., 2017, vol. 8, p. 1589.","journal-title":"Front. Immunol."},{"key":"7574_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/14740338.2021.1960981","volume":"21","author":"B. Caron","year":"2022","unstructured":"Caron, B., Jouzeau, J.Y., Miossec, P., Petitpain, N., Gillet, P., Netter, P., and Peyrin-Biroulet, L., Gastroenterological safety of IL-17 inhibitors: a systematic literature review, Expert Opin. Drug Saf., 2022, vol. 21, no.\u00a02, pp. 223\u2013239.","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924701084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672924701084","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924701084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:21:36Z","timestamp":1773760896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672924701084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7574"],"URL":"https:\/\/doi.org\/10.1134\/s1607672924701084","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved at a meeting of the independent interdisciplinary Committee for Ethical Review of Clinical Research (protocol No. 8 dated April 24, 2020). Before inclusion in the study, all study participants gave written informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}},{"value":"The authors are solely responsible for submitting the final version of the manuscript for publication. All authors took part in developing the concept of the article and writing the manuscript. The final version of the manuscript was approved by all authors. The authors did not receive any royalties for the article. Conflict of interest did not influence the results of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}},{"value":"Yu.V. Usacheva and O.V. Mironenko are employees of the BIOCAD JSC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"ADDITIONAL INFORMATION"}}]}}